Surgical Oncology
From the Journals
Consider adding chemotherapy after GI surgery
Average survival rates at 3 years after surgery were 40 months for those who received adjuvant chemotherapy vs. 34 months for those who did not....
Conference Coverage
‘Very daring study’ of neoadjuvant AI/CDKi combo in early BC is hypothesis generating
The nonchemo neoadjuvant regimen offered a slightly higher residual cancer burden prior to surgery, but a significantly better safety profile than...
Conference Coverage
Calcitonin-to-CEA ratio predicts medullary thyroid cancer survival
Can a ratio of serum calcitonin to carcinoembryonic antigen predict survival in patients with medullary thyroid cancer?
Conference Coverage
Mitotic rate not tied to SLN biopsy results in thin melanomas
SAN FRANCISCO – A survey of melanoma cases showed no correlation between mitotic rate in thin tumors and positive sentinel lymph node biopsy.
From the Journals
Surgeons strongly influenced chances of contralateral prophylactic mastectomy
Only 4% of patients elected CPM when their surgeons were among those who least favored it overall.
From the Journals
Ten-year outcomes support skipping axillary lymph node dissection with positive sentinel nodes
Ten-year overall survival was 86.3% in the sentinel lymph node dissection group, compared with 83.6% in the axillary lymph node dissection group,...
Conference Coverage
Minimally invasive esophagectomy may mean less major morbidity
COLORADO SPRINGS – Shorter LOS also seen in ACS-NSQIP analysis
Conference Coverage
Big changes coming for thyroid cancer staging
How big an impact will new thyroid staging criteria have on the numbers of stage I disease? It’ll be huge.
Feature
Cancer the most common diagnosis in palliative care patients
Survey shows that hospitalists are the main source of referrals to palliative care programs.
Conference Coverage
Contralateral nodal thyroid metastases show slow progression
BOSTON – In some thyroid cancers, a small level III contralateral nodal metastasis may be watched safely rather than resected.
Conference Coverage
Revised thyroid Bethesda System resets malignant risks
BOSTON – Revised thyroid cancer cytology system “limits malignancy to cases with features of classic malignant papillary thyroid carcinoma.”